What is the standard first-line treatment for pulmonary tuberculosis?

New patients with pulmonary tuberculosis require a structured, combination oral regimen to achieve cure, prevent the emergence of resistance, and eliminate ongoing transmission. The approach follows a defined sequential course with clear, measurable treatment targets.

Treatment approach

The recommended regimen for new patients with pulmonary TB is a combination of oral anti-tuberculosis drugs administered daily, delivered in two sequential phases across the full course — the complete drug selection, phasing, and clinical decision framework are available in the full protocol.

Clinical goals

Conversion of sputum culture to negative is the most important marker of response. Classic TB symptoms — cough, sputum production, fever, and weight loss — are expected to improve within the first few weeks and within 1–2 months of starting treatment.

Instant Access to Structured Evidence-Based Regimens

References

New patients with pulmonary TB should receive a regimen containing 6 months of rifampicin: 2HRZE/4HR.
The regimen is a combination of those four drugs (i.e. HRZE) for 2 months followed by isoniazid and rifampicin (i.e. HR) for 4 months, administered daily.
Wherever feasible, the optimal dosing frequency for new patients with pulmonary TB is daily throughout the course of therapy.
For pulmonary DS-TB, the most important evidence of improvement is conversion of the sputum culture to negative.
The classic symptoms of TB – cough, sputum production, fever and weight loss – generally improve within the first few weeks of treatment.

View source ↗